Drug Class: Topoisomerase II inhibitor; semisynthetic podophyllotoxin derivative

Mechanism of Action

Inhibits topoisomerase II, preventing the re-ligation of DNA double-strand breaks during replication. This leads to accumulation of DNA damage → cell cycle arrest in late S and G₂ phase → apoptosis.

Indications

Formulations: IV solution (etoposide phosphate also available), oral capsules (50% bioavailability → oral dose ≈ 2× IV dose)

Adult Dosing

Pediatric Dosing: Commonly 100–150 mg/m²/day IV × 3–5 days depending on protocol.

Renal Dose Adjustment

  • CrCl 15–50 mL/min → 75% of usual dose
  • CrCl <15 mL/min → 50% of usual dose
  • Hemodialysis → avoid or give post-dialysis

Hepatic Dose Adjustment: Consider dose reduction if bilirubin >1.5–3× ULN or AST >3× ULN.

Pharmacokinetics

  • Bioavailability ~50% (oral)
  • t½ ~4–11 h
  • Metabolism: hepatic (CYP3A4) & renal excretion (~40% unchanged in urine)

Key Toxicities

Drug Interactions

  • CYP3A4 inducers/inhibitors alter exposure
  • Concurrent nephrotoxic drugs ↑ toxicity risk

Monitoring

  • CBC prior to each cycle
  • Renal and hepatic function
  • Blood pressure during infusion

Counseling Points

  • Oral doses should be taken on an empty stomach
  • Report fever or infection signs promptly
  • Avoid live vaccines during therapy

Clinical Pearls

  • Infusion-related hypotension risk is rate-dependent → slow infusion
  • Oral dosing requires doubling the IV dose for equivalent exposure
  • Etoposide phosphate is water-soluble, avoiding precipitation issues and hypersensitivity from polysorbate 80
Synonyms
Toposar, Vepesid
Links